OncoMatch/Clinical Trials/NCT03582124
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Is NCT03582124 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Panitumumab-IRDye800 for lung carcinoma.
Treatment: Panitumumab-IRDye800 — This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Disease stage
Required: Stage IV, IVA, IVB (AJCC v8)
Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Performance status
KARNOFSKY/ECOG/ZUBROD 0–2
Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2
Prior therapy
Cannot have received: investigational drug
Lab requirements
Blood counts
hemoglobin ≥ 9 gm/dl; white blood cell count > 3000/mm^3; platelet count ≥ 100,000/mm^3
Kidney function
serum creatinine ≤ 1.5 times upper reference range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University, School of Medicine · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify